Director's Dealing • Dec 5, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
| FORM 4 | OMB APPROVAL | |||||||
|---|---|---|---|---|---|---|---|---|
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses) |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
OMB Number: Estimated average burden hours per response |
3235-0287 0.5 |
|||||
| 1. Name and Address of Reporting Person * Chen Lichtenstein |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person Form filed by More than One Reporting Person |
||||||
| (Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 12/02/2025 |
||||||
| (Street) Tel Aviv, L3 6944020 |
4. If Amendment, Date Original Filed (Month/Day/Year) | |||||||
| (City) (State) |
(Zip) |
Disposed of (D) (Instr. 3, 4 and 5)
Code V Amount (A) or (D) Price
Following Reported Transaction(s)
Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
of Indirect Beneficial Ownership (Instr. 4)
(Instr. 3 and 4)
Date (Month /Day/Year)
Execution Date, if any (Month/Day /Year)
Code (Instr. 8)
Ordinary Shares (1) 12/02/2025 M 4,804 A (2) 4,804 D
(Instr. 3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month /Day/Year) |
3A. Deemed Execution Date, if any (Month/Day /Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially |
10. Ownership Form of Derivative Security: |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable Expiration Date | Title | Amount or Number of Shares |
Owned Following Reported Transaction (s) (Instr. 4) |
Direct (D) or Indirect (I) (Instr. 4) |
|||||||
| Restricted Share Units |
(2) | 12/02/2025 | M | 4,804 | (3) | (3) | Ordinary Shares (1) |
4,804 | \$ 0 | 0 | D |
/s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein 12/04/2025 Signature of Reporting Person ** Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.